The Danish pharmaceutical giant is fighting on several fronts at once—and the market can’t seem to agree on whether that’s a reason for concern or confidence.
Novo Nordisk has filed 130 federal lawsuits against telemedicine providers and compounding pharmacies distributing unauthorized copies of its GLP-1 treatments, a legal campaign waged jointly with Eli Lilly that has quietly become one of the company’s most expensive side battles. The patent protection that once formed the bedrock of its business model is now under assault from multiple directions, including a fresh challenge from Russian competitor Geropharm, which has initiated legal proceedings to access five Novo Nordisk patents after earlier attempts to launch generic versions of Ozempic and Wegovy.
Yet even as the lawyers stay busy, the company is pushing forward on expansion. China’s drug regulator NMPA has accepted the marketing application for the oral version of Wegovy as a weight-loss treatment—a significant step in the race against Eli Lilly’s oral orforglipron on one of the world’s largest obesity markets, following the drug’s 2024 approval in the country as a diabetes medication.
A Buyback That Speaks Louder Than Words
Between August 17 and 21, Novo Nordisk repurchased 1,045,000 B-shares at prices ranging from 292.60 to 299.08 Danish kroner, bringing its total holdings to 43,969,876 B-shares—roughly one percent of its total share capital. The buyback is part of a 15-billion-kroner program spanning twelve months.
That’s a classic signal from management: they believe their own stock is undervalued, even if the market appears to disagree. The share price closed Friday at 39.41 euros, down 13 percent over the past 30 days and sitting 28 percent below its 52-week high of 54.86 euros from late January. The 50-day moving average of 41.81 euros sits above the current price, underscoring the recent weakness.
Wall Street’s Split Personality
The analyst community is sharply divided on what comes next. Deutsche Bank downgraded the stock to “Sell” in late August, cutting its price target by 9 percent to 265 Danish kroner, citing doubts about a return to growth in 2027, intensifying competition from Eli Lilly, and the failure of the late-stage clinical trial for Ziltivekimab in the cardiovascular indication.
Just days earlier, JPMorgan moved in the opposite direction, raising its price target to 275 from 250 Danish kroner while maintaining a neutral rating, supported by improved growth prospects for Ozempic and Wegovy outside the United States. Two major banks, nearly identical calendar weeks, diametrically opposed conclusions—a telling snapshot of just how fractured the Street’s view has become.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Separating Fresh News From Familiar Noise
Some of the recent headlines warrant context. The FDA’s warning letter to Novo Nordisk regarding inadequately reported side effects for Ozempic and Wegovy was delivered back in early March, not recently. The company says it is addressing the agency’s concerns—this is already part of the known record, not a new shock.
Similarly, Scholar Rock’s decision to remove a Catalent facility in Indiana—a Novo Nordisk subsidiary—from its marketing application for Apitegromab, following an “Official Action Indicated” designation from the FDA there, is not a direct approval setback for Novo Nordisk. But it does signal that manufacturing quality within the company’s orbit is under regulatory scrutiny, which could make other partners nervous.
Pipeline Progress Amid the Noise
The operational engine, meanwhile, keeps turning. Phase 1b/2a data for subcutaneous Amycretin showed up to 24.3 percent weight reduction at the 60-mg dose over 36 weeks, forming the basis for the newly launched Phase 3 study AMAZE 1. The OASIS-5 study of lower maintenance doses of the oral Wegovy pill has been running since late August, with roughly 450 participants and a timeline extending to April 2028.
South Korea’s health authority has also given the green light for Phase 3 clinical trials of Zenagutide, a novel dual-acting obesity drug that demonstrated 14.6 percent weight loss in Phase 2. The company plans to launch the global Phase 3 program for the compound in the second half of 2026, with the Korean approval serving as one component of that worldwide effort.
What Investors Are Watching
Two dates now dominate the calendar. On September 21, Novo Nordisk hosts its Capital Markets Day, where management has promised updates on long-term growth strategy and pipeline developments. On November 4, third-quarter 2026 results are due.
The technical picture offers little clarity: the RSI of 43.3 signals neither oversold conditions nor euphoria—the market is simply searching for direction. Whether the growth story—anchored by China, new drug candidates like Zenagutide, and international Wegovy expansion—can outshine the legal and regulatory headwinds remains the central question. For now, the buybacks and the Chinese filing carry more substance than the overstated readings of older regulatory matters. The Capital Markets Day should reveal whether management can translate that substance into a convincing growth narrative for 2027. Until then, this remains a stock for investors with steady nerves—not the impatient kind.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 29 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 29.
Novo Nordisk: Buy or sell? Read more here...
